Tourette's study stopped early as tic severity falls
This article was originally published in Scrip
Executive Summary
Psyadon Pharmaceuticals' Phase II study of ecopipam in patients with Tourette Syndrome has been stopped early as a planned interim analysis revealed a significant reduction in the severity of the patients' tic symptoms.